Combing through the data of its most recent setback in Alzheimer’s disease, Merck (MRK) sees a glimmer of hope that a once-failed drug might come through for patients in the earliest stages of disease.
Merck’s drug, verubecestat, was virtually indistinguishable from placebo in a trial involving roughly 2,000 patients with mild or moderate Alzheimer’s, the company revealed Thursday. Over 18 months, patients saw their cognition, function, and dementia grow worse regardless of whether they got verubecestat or a sugar pill, and no matter whether their disease was mild or moderate. The results were so decisively negative that Merck ended the trial five months early.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
